Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decision analysis in formulary decision making.

C B Schechter1

  • 1Department of Community Medicine, Mount Sinai School of Medicine, New York.

Pharmacoeconomics
|May 8, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlates of self-rated health in people with diabetic peripheral neuropathy: a longitudinal study.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Reply to Koleva-Kolarova et al.

Breast (Edinburgh, Scotland)·2016
Same author

Dimensional structure and course of post-traumatic stress symptomatology in World Trade Center responders.

Psychological medicine·2013
Same author

Trajectories of PTSD risk and resilience in World Trade Center responders: an 8-year prospective cohort study.

Psychological medicine·2013
Same author

Abdominal diameter index: a more powerful anthropometric measure for prevalent coronary heart disease risk in adult males.

Diabetes, obesity & metabolism·2005
Same author

Outcome prediction model for very elderly critically ill patients.

Critical care medicine·2001
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Quantitative methods for drug formulary decisions are underutilized and often flawed. Effective analysis requires institution-specific data beyond acquisition costs for accurate economic impact assessment.

Area of Science:

  • Health Economics
  • Decision Science
  • Pharmaceutical Policy

Background:

  • Quantitative techniques like decision analysis are suitable for formulary decisions but are rarely published.
  • Existing decision analyses often use unproven methods, potentially distorting drug attribute evaluation.

Purpose of the Study:

  • To review the literature on quantitative techniques for institutional formulary decision-making.
  • To identify limitations in current decision analysis methods for drug formulary assessment.

Main Methods:

  • Literature review of published decision analyses and cost-benefit analyses for drug formulary inclusion.
  • Critical evaluation of methodologies used in existing studies.

Main Results:

Related Experiment Videos

  • Drug acquisition costs alone are insufficient for evaluating formulary decisions; labor and material costs are crucial and institution-specific.
  • Clinical studies often lack the scope or standardization needed for comprehensive formulary assessments.
  • Gathering institution-specific data is challenging and often discouraged by institutional structures.

    • Conclusions:

    • There is a need for more rigorous and standardized application of decision analysis in formulary management.
    • Future research should focus on developing valid, institution-specific methods for evaluating drug attributes and economic impact.
    • Addressing institutional barriers is essential for improving the quality of formulary decision-making.